Lurasidone

Routes
Oral (PO)
Half-Life (t½)
PO: 18h
Formula
C28H36N4O2S
Molecular Weight
492.68 g/mol
PubChem CID
213046
Aliases
Latuda, SM-13496

Pharmacological Mechanism

Second-generation antipsychotic with high-affinity D2 and 5-HT2A antagonism, 5-HT7 antagonism, 5-HT1A partial agonism, and negligible H1 / M1 / α1 activity — predicts a favourable metabolic and sedation profile relative to older atypicals. Oral bioavailability is ~2× with a ≥350 kcal meal; FDA labelling requires food co-administration.

Half-Life & Elimination Curve (PO: 18h)

100%50%25%12.5%0%0h0×t½18h1×t½36h2×t½54h3×t½3d4×t½3.8d5×t½0×t½ (0h): 100% remaining (~26.5 µg/L)1×t½ (18h): 50% remaining (~13.2 µg/L)2×t½ (36h): 25% remaining (~6.61 µg/L)3×t½ (54h): 12.5% remaining (~3.31 µg/L)4×t½ (3d): 6.3% remaining (~1.65 µg/L)5×t½ (3.8d): 3.1% remaining (~0.827 µg/L)
Plasma (PO)t½ Decay (18h)Effect Site (ke0)
  • 0×t½0h100% (26.5 µg/L)
  • 1×t½18h50% (13.2 µg/L)
  • 2×t½36h25% (6.61 µg/L)
  • 3×t½54h12.5% (3.31 µg/L)
  • 4×t½3d6.3% (1.65 µg/L)
  • 5×t½3.8d3.1% (0.827 µg/L)
Elimination t½18h (PO)
Rate Constant (ke)0.0385 h⁻¹
Time to Peak (Tmax)2h
Est. Peak (Cmax)26.5 µg/L
Clearance (CL)16.2 L/h
97% Washout (5×t½)3.8d

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References